Connect with us

News

Cannabotech one step closer to bringing cancer products to patients

Sales of its products are expected to start in California in 2022, with the goal to later launch in the UK.

Published

on

Cannabotech one step closer to bringing cancer products to patients
Cannabotech's products are expected to be available for patients in California later this year.

Israeli company, Cannabotech, has partnered with California-based Go NXT LVL to manufacture oncology products for patients in the state.

Cannabotech, an Israeli startup that develops botanical solutions for integrative oncology and preventive medicine, has announced a new strategic partnership with the Californian corporation Go NXT LVL.

This agreement will allow Cannabotech’s integrative oncology products to be developed and manufactured at Go NXT LVL’s facilities in accordance with the California Medical Cannabis Regulations. 

The move marks the next phase in Cannabotech’s efforts to bring its products to market. Sales to oncologists and integrative caregivers  are expected to start in California later this year, with a view to expanding into the UK and Israel. 

Cannabotech also intends to make its research accessible to Californian doctors, including the ongoing studies on products designed to help patients with breast cancer, colon cancer, pancreatic cancer, lung cancer, prostate cancer and chemotherapy side effects such as neuropathic and inflammatory pain.

The company recently announced cell model study results, showing that its Integrative-Colon products killed “over 90 per cent” of cancer cells.

It came following the findings that products designed to target pain and inflammation, reduced symptoms by more than 80 per cent.

Its integrative oncology products will be available to senior oncologists and therapists in the state, as part of the conventional anti-cancer treatment they currently prescribe, with support from the company’s experts, including several senior Israeli oncologists.

California was the first in the world to approve medical cannabis regulations, as early as 1996, and its cannabis market is one of the most mature in the world, estimated to be worth over $4.5billion in 2012.

Go NXT LVL, has licenses for the production and distribution of medical cannabis products, as well as a distribution network for medical cannabis products through which it advises patients, provides them with medical prescriptions, and delivers products to their homes. 

Read more: Cannabotech sets sights on the UK CBD market

Its facilities, located in Desert Hot Springs, are in an area exempt from municipal cannabis taxes, which according to the company allows them to produce cannabis products at “competitive prices”. 

Cannabotech CEO, Elhanan Shaked, said: “This is a significant milestone in Cannabotech’s growth, allowing us entry into the world’s largest cannabis market, with unique medical solutions that will be specific and distinct from all other players in this arena. 

“We are excited about finding such a professional partner as Go NXT LVL, with their ability to develop and manufacture Cannabotech’s complex formulae while adhering to local medical cannabis regulations.”

Shaked added: “The vision and path we established three years ago are now becoming a reality, and we are very proud of building a solid intellectual property in Israel and starting to commercially sell our products in the world’s largest cannabis market before the end of this year.”

 

Home » News » Cannabotech one step closer to bringing cancer products to patients

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister title and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email sarah@prohibitionpartners.com / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.